Free tool
FAERS Monitor: Vosevi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209195 or its brand name (Vosevi, Sofosbuvir, Velpatasvir, Voxilaprevir). Reports on generic versions are filed under their own applications.
Reports
1,086
Serious
405
37% of reports
Hospitalization
81
Death reported
35
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue197
- headache134
- treatment failure115
- drug ineffective108
- nausea104
- hepatitis c91
- diarrhoea86
- vomiting36
- insomnia29
- abdominal discomfort23
- hepatocellular carcinoma22
- product dose omission20
- intentional dose omission19
- pruritus19
- asthenia18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 80 |
| 2018 | 363 |
| 2019 | 275 |
| 2020 | 133 |
| 2021 | 72 |
| 2022 | 46 |
| 2023 | 40 |
| 2024 | 19 |
| 2025 | 43 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,073 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis cSignal | 91 | 147.1 | 120.7 | 12,967 |
| hepatocellular carcinomaSignal | 22 | 56.2 | 37.1 | 1,135 |
| treatment failureSignal | 115 | 26.9 | 22.6 | 2,852 |
| intentional dose omissionSignal | 19 | 12.9 | 8.3 | 197 |
| product dose omissionSignal | 20 | 5.9 | 3.8 | 77 |
| fatigueSignal | 197 | 4.9 | 4.3 | 631 |
| headacheSignal | 134 | 4.1 | 3.5 | 326 |
| abdominal discomfortSignal | 23 | 2.7 | 1.8 | 22 |
| diarrhoeaSignal | 86 | 2.6 | 2.1 | 84 |
| nauseaSignal | 104 | 2.5 | 2.1 | 100 |
| insomniaSignal | 29 | 2.1 | 1.5 | 16 |
| drug ineffective | 108 | 1.6 | 1.3 | 24 |
| vomiting | 36 | 1.5 | 1.1 | 5 |
| pruritus | 19 | 1.0 | 0.6 | 0 |
| asthenia | 18 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.